This company has been acquired

NYSE:MYOV Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 22	379	-184	317	-1
30 Sep 22	333	-190	303	0
30 Jun 22	306	-166	277	0
31 Mar 22	231	-206	259	0
31 Dec 21	198	-228	244	72
30 Sep 21	145	-238	222	0
30 Jun 21	67	-284	194	0
31 Mar 21	59	-255	156	0
31 Dec 20	35	-239	126	11
30 Sep 20	33	-250	96	-102
30 Jun 20	33	-254	81	-51
31 Mar 20	0	-289	82	0
31 Dec 19	0	-299	62	59
30 Sep 19	0	-284	54	219
30 Jun 19	0	-279	48	222
31 Mar 19	0	-274	42	0
31 Dec 18	0	-247	37	204
30 Sep 18	0	-218	33	180
30 Jun 18	0	-182	29	150
31 Mar 18	0	-143	24	117
31 Dec 17	0	-117	21	96
30 Sep 17	0	-83	17	67
30 Jun 17	0	-88	14	47
31 Mar 17	0	-83	12	44

Quality Earnings: MYOV is currently unprofitable.

Growing Profit Margin: MYOV is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MYOV is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare MYOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.4%).

Return on Equity

High ROE: MYOV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth


Price	7D	1Y
Mkt Cap	P/E	Growth

This company has been acquired

Myovant Sciences Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant May Delist from the New York Stock Exchange

Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion.

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Principal Financial Officer recently sold US$174k worth of stock

Women Can Thank Pfizer And Myovant For MYFEMBREE

Myovant Sciences: Regulatory Overhang Cleared

General Counsel & Corporate Secretary recently sold US$569k worth of stock

Price target increased to US$20.40

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Myovant stock gains ~6% after hours on Q1 revenue jump

CEO & Director recently sold US$144k worth of stock

Consensus EPS estimates fall by 29%

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Price target decreased to US$22.80

Less than half of directors are independent

Myovant: Poised To Overcome Regulatory Issues

General Counsel & Corporate Secretary recently sold US$84k worth of stock

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Price target decreased to US$24.80

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold US$292k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold US$73k worth of stock

Myovant: Catalysts Powering More Upside

Chief Medical Officer exercised options and sold US$62k worth of stock

Price target decreased to US$28.40

General Counsel & Corporate Secretary recently sold US$144k worth of stock

Chief Medical Officer exercised options and sold US$116k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Price target decreased to US$33.25

Chief Medical Officer exercised options and sold US$342k worth of stock

Less than half of directors are independent

Key Executive recently sold US$70k worth of stock

Myovant Sciences: Becoming A Blockbuster

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences rises on FDA approval for relugolix

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment

Consensus forecasts updated

General Counsel & Corporate Secretary recently sold US$202k worth of stock

General Counsel & Corporate Secretary notifies of intention to sell stock

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Analysts update estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Revenue and earnings miss expectations

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Analysts increase revenue estimates to US$42.9m

Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Myovant Sciences Ltd Appoints David Marek as Principal Executive Officer and Member of the Board of Directors

Revenue & Expenses Breakdown
Beta